



Form PTO-1449 (modified)

Atty. Docket No.
DEBE:028USSerial No.
10/743,697

Office of Patents and Publications for Applicant's

Applicant
Peter Kufer *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 22, 2003Group:
~~Unknown~~ 1644U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
P/B	B3	WO 01/040312	1/18/01	PCT			Abstract
↓	B4	WO 01/090190	11/29/01	PCT			English
↓	B5	WO 03/035694	5/01/03	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation

25410044.1

EXAMINER:

DATE CONSIDERED:

3/22/02

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
DEBE:028USSerial No.
10/743,697

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Peter Kufer *et al.*Filing Date:
December 22, 2003Group:
Unknown 164fU.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
Pkt	A1	5,258,498	11/02/93	Huston and Oppermann	530	350	5/19/88
Pkt	A2	5,525,491	6/11/96	Huston <i>et al.</i>	435	69.7	6/09/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
Pkt	B1	EP 573 551	5/21/03	Europe			
Pkt	B2	EP 623 679	11/09/94	Europe			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Pkt	C1	Baynex, "Recombinant protein expression in Escherichia coli," <i>Curr. Opin. Biotech.</i> , 10:411-421, 1999.
	C2	Bohlen <i>et al.</i> , "Cytolysis of Leukemic B-cells by T-cells activated via two bispecific antibodies," <i>Cancer Res.</i> , 53:4310-4314, 1993.
	C3	Brühl, "Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV," <i>J. Immunol.</i> , 166:2420-2406, 2001.
	C4	Cortez-Retamozo <i>et al.</i> , "Efficient tumor targeting by single-domain antibody fragments of camels," <i>Int. J. Cancer</i> , 98:456-462, 2002.
	C5	Davies and Reichmann, "Antibody VH domains as small recognition units," <i>Biotechnology</i> , 13:475-479, 1995.
✓	C6	Davies and Riechmann, "Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability," <i>Protein Engineering</i> , 9(6):531-537, 1996.

25373241.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
DEBE:028USSerial No.
10/743,697Applicant
Peter Kufer *et al.*Filing Date:
December 22, 2003Group:
~~Unknown~~ 1644

U.S. Patent and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Patt	C7	De Jonge <i>et al.</i> , "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotypic) induces long-term survival in the murine BCL1 lymphoma model," <i>J. Immunol.</i> , 161:1454-1461, 1998.
	C8	Desmyter <i>et al.</i> , "Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody," <i>J. Biol. Chem.</i> , 276(28):26285-26290, 2001.
	C9	Desmyter <i>et al.</i> , "Three camelid VHH domains in complex with porcine pancreatic α -amylase," <i>J. Biol. Chem.</i> , 277(26):23645-23650, 2002.
	C10	Dumoulin <i>et al.</i> , "Single-domain antibody fragments with high conformational stability," <i>Protein Science</i> , 11:500-515, 2002.
	C11	Conrath <i>et al.</i> , "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs," <i>J. Biol. Chem.</i> , 276(10):7346-7350, 2001.
	C12	Ewert <i>et al.</i> , "Biophysical properties of camelid VHH domains compared to those of human VH3 domains," <i>Biochemistry</i> , 41:3628-3636, 2002.
	C13	Harmsen <i>et al.</i> , "Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features," <i>Molecular Immunology</i> , 37:579-590, 2000.
	C14	Jobling <i>et al.</i> , "Immunomodulation of enzyme function in plants by single-domain antibody fragments," <i>Nature Biotech.</i> , 21:77-80, 2003.
	C15	Kufer <i>et al.</i> , "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer," <i>Cancer Immunol. Immunother.</i> , 45:193-197, 1997.
	C16	Löffler <i>et al.</i> , "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes," <i>Blood</i> , 95(6):2098-2103, 2000.
	C17	Mack <i>et al.</i> , "Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3," <i>J. Immunol.</i> , 158:3965-3970, 1997.
✓	C18	Mack <i>et al.</i> , "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity," <i>Proc. Natl. Acad. Sci., USA</i> , 92:7021-7025, 1995.

25373241.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.
DEBE:028USSerial No.
10/743,697Applicant
Peter Kufer *et al.*Filing Date:
December 22, 2003Group:
Unknown *1601*U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>Pkt</i>	C19	Muruganandam <i>et al.</i> , "Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium," <i>FASEB Journal</i> , 16:240-242, 2002.
	C20	Muyldermans <i>et al.</i> , "Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains," <i>Trends in Biochemical Sciences</i> , 26(4):230-235, 2001.
	C21	Riechmann, "Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain," <i>J. Mol. Biol.</i> , 259:957-969, 1996.
	C22	Spinelli <i>et al.</i> , "Camelid heavy-chain variable domains provide efficient combining sites to haptens," <i>Biochemistry</i> , 39:1217-1222, 2000.
✓	C23	Tanha <i>et al.</i> , "Optimal design features of camelized human single-domain antibody libraries," <i>J. Biol. Chem.</i> , 276(27):24774-24780, 2001.

25373241.1

EXAMINER:

DATE CONSIDERED:

3/22/06

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)